Gelfand Clinical Research Lab

Publications

Publications  

• For an extensive list of Dr. Gelfand's research publications, please refer here.

• Some of the Gelfand lab’s most important findings in the last decade:

  ·    2010

  First to show severe psoriasis is a risk factor for CV mortality: https://www.ncbi.nlm.nih.gov/pubmed/20037179

  ·   2011

  TNF monotherapy without signal for infection or cancer in meta-analysis of psoriasis RCTs: https://www.ncbi.nlm.nih.gov/pubmed/21315483

  First to show psoriasis is associated with increased aortic vascular inflammation, setting up a series of trials: https://www.ncbi.nlm.nih.gov/pubmed/21576552

  ·  2012

  Biologics have lower effectiveness in real world settings: https://www.ncbi.nlm.nih.gov/pubmed/22508874

  ·  2013

  We are the first to show psoriasis is a risk factor for chronic kidney disease: https://www.ncbi.nlm.nih.gov/pubmed/24129480

  ·   2014

  Clear skin is more important than almost clear skin for psoriasis, setting up new performance measures: https://www.ncbi.nlm.nih.gov/pubmed/24928705

  ·  2015

  HTN poorly controlled in patients with psoriasis, as skin severity increases, HTN gets worse: https://www.ncbi.nlm.nih.gov/pubmed/25322196

  Risk of MACE similar in psoriasis compared to rheumatoid arthritis: https://www.ncbi.nlm.nih.gov/pubmed/25351522

  BSAxPGA correlates well with PASI. This measure is now routinely used in simplified clinical trials: https://www.ncbi.nlm.nih.gov/pubmed/26475541

  ·  2016

  The risk of cancer in psoriasis is small and is driven by NMSC, lymphoma, and lung cancer: https://www.ncbi.nlm.nih.gov/pubmed/26676102

  ·  2017

  We provide a seminal review for clinicians re: comorbidity and psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/28212760

  ·   2018

  The risk of venous thromboembolic disease varies between Pso, PsA, and RA: https://www.ncbi.nlm.nih.gov/pubmed/28444172

  Body surface area predicts mortality and diabetes  in psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/28843488

  https://www.ncbi.nlm.nih.gov/pubmed/29128465

  Liver disease is more strongly associated with Pso and PsA than with RA:

  https://www.ncbi.nlm.nih.gov/pubmed/29104161

  We defined the CV effects of adalimumab and phototherapy vs placebo:

  https://www.ncbi.nlm.nih.gov/pubmed/29776990

  ·  2019:

  Stigmatizing views about psoriasis remain widely held in the US: https://www.ncbi.nlm.nih.gov/pubmed/30171876

  Phototherapy achieves similar and potentially better patient reported outcomes compared to adalimumab:  https://www.ncbi.nlm.nih.gov/pubmed/31163241

  We launched the LITE study, a pragmatic trial of home v office phototherapy:

  www.thelitestudy.com

Lectures 

• Psoriasis and Cardiometabolic Disease: More than skin deep